Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer

Min Huang,Peter A. Fasching,Amin Haiderali,Weiguang Xue,Wilbur Pan,Vassiliki Karantza,Fan Yang,James E. Truscott,Yiqiao Xin,Joyce O’Shaughnessy
DOI: https://doi.org/10.2217/fon-2023-0315
2024-01-01
Future Oncology
Abstract:Aim: This study evaluated event-free survival (EFS) as a surrogate outcome for overall survival (OS) in neoadjuvant therapy for early-stage triple-negative breast cancer (eTNBC). Methods: Meta-regression analyses based on a targeted literature review were used to evaluate the individual- and trial-level associations between EFS and OS. Results: In the individual-level analyses, 3-year EFS was a significant predictor of 5-year OS (p < 0.01; coefficient of determinations [R 2 ]: 0.82 [95% CI: 0.68–0.91]). Additionally, there was a statistically significant association between the treatment effect on EFS and OS at the trial level (p < 0.001; R 2 : 0.64 [95% CI: 0.45–0.82]). Conclusion: This study demonstrates significant associations between EFS and OS and suggests that EFS is a valid surrogate for OS following neoadjuvant therapy for eTNBC.
What problem does this paper attempt to address?